AURA
Aura Biosciences, Inc.
NASDAQ · Healthcare · Biotechnology · US
$6.65
+6.57%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$6.42
From 52W high−25.28%
Volume982215.00
Market cap$689.64M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataNov 4, 2026
Open
$6.42
From 52W high
−25.28%
Volume
982215.00
Market cap
$689.64M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−2.9x
P/E (TTM)
—
RSI (14)
49.2
MomentumView details →
1D Return
+6.57%
YTD Return
+16.15%
SummaryUpdated Jun 1, 2026
Aura Biosciences, Inc. (NASDAQ:AURA) is a clinical-stage biotechnology company founded in 2009 and headquartered in Cambridge, Massachusetts. The company went public in October 2021 and focuses on developing innovative cancer therapies using its proprietary virus-like drug conjugate (VDC) technology platform. Aura specializes in treating rare and difficult-to-treat cancers, particularly in ocular (eye-related) and urologic oncology where significant unmet medical needs exist.
Similar companies
Latest newsMore news →
Aura Biosciences reported a net loss of $45.6 million for Q2 2026, with diluted EPS of -$0.48, and announced a 20% workforce reduction as part of an organizational realignment, expecting cash runway into the first half of 2029.86d agoAura Biosciences appointed Jeremy Bender as a Class II director effective July 7, 2026.120d ago